Genentech Grabs Breakthrough Approval for Chronic Leukemia Drug Gazyva

Published: Nov 05, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The FDA today approved its first “breakthrough” medicine—Genentech’s Gazyva™ (obinutuzumab or GA101), in combination with chlorambucil chemotherapy for people with previously untreated chronic lymphocytic leukemia (CLL). The Roche subsidiary trumpeted the approval as FDA’s fifth for a new drug developed by the company in the past three years. Gazyva is the first approved drug to have been designated a Breakthrough Therapy by the FDA.

Help employers find you! Check out all the jobs and post your resume.

Back to news